Strategic Acquisition StrataDx recently agreed to be acquired by Fulgent Genetics, signaling potential continuity in ongoing clinical partnerships and a shift in governance. This creates an opening to engage with the new leadership on contract renewals, integration of laboratory services, and cross-sell of advanced molecular pathology capabilities.

Molecular Diagnostics With a proven track record in molecular diagnostic and prognostic techniques and the DermSTAT DNA test launch, there is a clear opportunity to offer expanded molecular panels, genomics-based testing, and customized diagnostic workflows to hospitals and dermatology-focused practices.

Dermatopathology Focus Leadership in dermatopathology and skin infection DNA testing positions StrataDx to grow partnerships with dermatology networks, wound care centers, and allergy/immunology clinics that require specialized, timely diagnostic support and streamlined reporting.

Scale and Reach Despite a mid-size footprint, StrataDx competes with larger labs through specialized expertise. There is potential to propose scalable, white-label pathology solutions, 24/7 support, and integrated LIS/Salesforce-driven workflows to multi-site health systems seeking consistent service quality.

Growth Readiness Revenue range indicates a growth-ready, mid-market pathology provider. Target expansion opportunities include national hospital networks, private equity-backed pathology platforms, and regional health systems looking to consolidate diagnostics and reduce turnaround times.